文献速递妇科

帕博利珠单抗联合仑伐替尼治疗复发性子宫内膜癌:推荐剂量与减量起始的毒性与疗效比较

Toxicity and efficacy of the combination of pembrolizumab with recommended or reduced starting doses of lenvatinib for treatment of recurrent endometrial cancer.
PubMed 文献 · Gynecol Oncol · 2021-05-03

该回顾性研究分析了70例复发性子宫内膜癌患者,比较帕博利珠单抗联合仑伐替尼推荐起始剂量(20 mg)与减量起始(<20 mg,最常见14 mg)的毒性和疗效。推荐剂量组因副作用平均减量次数更多、至毒性时间更短,但两组缓解率、无进展生存和总生存无显著差异;癌肉瘤组织学患者也观察到缓解。

要点

  • 减量起始仑伐替尼(最常见14 mg)联合帕博利珠单抗在复发性子宫内膜癌中安全有效。
  • 推荐剂量组因副作用平均减量次数显著更多(1.1 vs 0.4,p=0.003)。
  • 两组缓解率、无进展生存和总生存无显著差异。

核心结论

  • 临床实践中,较低起始剂量仑伐替尼(14 mg每日)联合帕博利珠单抗治疗复发性子宫内膜癌安全有效。
  • 该联合方案在子宫内膜癌肉瘤中产生缓解。
  • 需要更大规模研究验证这些发现。

研究设计与样本

  • 回顾性研究,纳入70例接受至少1周期帕博利珠单抗/仑伐替尼的复发性子宫内膜癌患者。
  • 按仑伐替尼起始剂量分组:推荐剂量组(20 mg)16例,减量组(<20 mg)54例。
  • 比较亚组间毒性、治疗反应和生存结局,并按组织学类型分析。

主要发现

  • 推荐剂量组因副作用平均减量次数显著高于减量组(1.1 vs 0.4;p=0.003)。
  • 推荐剂量组至治疗毒性中位时间显著短于减量组(1.3 vs 3.7天;p=0.0001)。
  • 推荐剂量组与减量组缓解率无显著差异(28.6% vs 38.3%;p=0.752)。
  • 减量组有2例完全缓解。
  • 癌肉瘤组织学患者缓解率和临床获益率分别为25%(3/12)和58.3%(7/12)。

关键数值与推荐

  • 仑伐替尼最常见起始剂量为14 mg每日。
  • 推荐剂量组因副作用平均减量次数1.1次,减量组0.4次(p=0.003)。
  • 推荐剂量组至毒性中位时间1.3天,减量组3.7天(p=0.0001)。
  • 推荐剂量组缓解率28.6%,减量组38.3%(p=0.752)。
  • 癌肉瘤患者缓解率25%(3/12),临床获益率58.3%(7/12)。

临床怎么用

  • 复发性子宫内膜癌可考虑帕博利珠单抗联合减量起始仑伐替尼(如14 mg每日)以平衡毒性与疗效。
  • 推荐起始剂量20 mg时需更密切监测毒性并及时减量。
  • 癌肉瘤组织学患者也可从该联合方案中获益。

局限性

  • 回顾性研究设计。
  • 样本量较小(共70例,推荐剂量组仅16例)。
  • 需要更大规模研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: We reviewed our institutional data to evaluate toxicity and efficacy outcomes of pembrolizumab/lenvatinib in recurrent endometrial cancer in a "real-world" clinical setting and to compare the impact of reduced lenvatinib starting dose on outcomes. METHODS: Retrospectively, we reviewed toxicity, treatment responses, and survival outcomes of patients with recurrent endometrial cancer who received ≥1 cycle of pembrolizumab/lenvatinib. We compared subgroups based on lenvatinib starting dose (recommended [20 mg] vs reduced [<20 mg]) and histologic type. RESULTS: We analyzed 70 patients (recommended dose cohort, n = 16; reduced dose cohort, n = 54). The most common starting dose was 14 mg daily. Compared to the reduced dose cohort, the recommended dose cohort had a significantly higher mean number of lenvatinib dose reductions due to side effects (1.1 vs. 0.4; p = 0.003) and significantly shorter median time to treatment toxicity (1.3 vs. 3.7 days; p = 0.0001). Response rates did not differ significantly between the recommended and reduced dose cohorts (28.6% vs. 38.3%, respectively; p = 0.752). Two patients, both in the reduced dose cohort, had complete responses. Patients with carcinosarcoma histology had response and clinical benefit rates of 25% (3 of 12) and 58.3% (7 of 12), respectively. There were no differences between the 2 dose cohorts with respect to progression-free (p = 0.245) or overall survival (p = 0.858). CONCLUSION: In clinical practice, a lower starting dose of lenvatinib (14 mg daily) in combination with pembrolizumab was safe and efficacious in recurrent endometrial cancer. The combination produced responses in endometrial carcinosarcomas. Larger studies are required to validate these findings.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. How JA, Patel S, Fellman B, et al. Toxicity and efficacy of the combination of pembrolizumab with recommended or reduced starting doses of lenvatinib for treatment of recurrent endometrial cancer. Gynecol Oncol. 2021. PMID: 33958211. doi:10.1016/j.ygyno.2021.04.034

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。